Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition

Journal of Cancer Research and Therapeutics

Volumn 11, Issue 2, 2015, Pages 336-340

  Richard, Silvina ^a,b   Martinez Marignac, Veronica ^c  

^a Instituto Multidisciplinario de Biologia Celular   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c UNIVERSIDAD NACIONAL DE ENTRE RÍOS   (Argentina)

Author keywords

5 FU; colorectal cancer; metformin; oxaliplatin; ribavirin

Indexed keywords

COMPOUND 968; FLUOROURACIL; HYDROLASE INHIBITOR; METFORMIN; OXALIPLATIN; RIBAVIRIN; SULFORHODAMINE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTAMINASE; PLATINUM COMPLEX;

ARTICLE; CELL VIABILITY; COLON CANCER; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIZATION; HCT116 CELL LINE; HT 29 CELL LINE; IC50; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HUMAN; MITOCHONDRION;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLUTAMINASE; HCT116 CELLS; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; METFORMIN; MITOCHONDRIA; ORGANOPLATINUM COMPOUNDS; RIBAVIRIN;

EID: 84937135395     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.157317     Document Type: Article

References (30)

1. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
2. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: A case-control analysis. Am J Gastroenterol 2012;107:620-6.
3. Borden KL, Culjkovic-Kraljacic B. Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and beyond? Leuk Lymphoma 2010;51:1805-15.
4. Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, Panasci L, Miller W, et al. Pharmacological targeting of eIF4E in primary CLL lymphocytes. Blood Cancer J 2013;3:e146.
5. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski LK, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 1972;177:705-6.
6. Yamada Y, Natsumeda Y, Weber G. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry 1988;27:2193-6.
7. Kozhevnikova EL, van der Knaap JA, Pindyurin AV, Ozgur Z, van Ijcken WF, Moshkin YM, et al. Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. Mol Cell 2012;47:133-9.
8. Collart FR, Chubb CB, Mirkin BL, Huberman E. Increased inosine-5′-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res 1992;52:5826-8.
9. Matassa DS, Amoroso MR, Agliarulo I, Maddalena F, Sisinni L, Paladino S, et al. Translational control in the stress adaptive response of cancer cells: A novel role for the heat shock protein TRAP1. Cell Death Dis 2013;4:e851.
10. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10:143-56.
11. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000;35:75-93.
12. Shi Y, Tang B, Yu VW, Tang B, Hao IX, Lei X, et al. Autophagy protects against oxaliplatin-induced cell death via ER stress and ROS in Caco-2 cells. PLoS One 2012;7:e51076.
13. Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 2010;46:1900-9.
14. Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O′Dwyer PJ. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res 2013;19:2995-3007.
15. Hensley CT, Wasti AT, DeBerardinis JR. Glutamine and cancer: Cell biology, physiology, and clinical opportunities. J Clin Invest 2013;123:3678-84.
16. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-6.
17. Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 2011;141:50-61.
18. Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng X, Nogueira V, et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006;10:269-80.
19. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008;99:2136-41.
20. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010;49:662-71.
21. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010;3:1077-83.
22. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011;30:1174-82.
23. Chen J, Huang XF, Qiao L, Katsifis A. Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol 2011;2:27-33.
24. Vizan P, Alcarraz-Vizan G, Diaz-Moralli S, Solovjeva ON, Frederiks WM, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 2009;124:2789-96.
25. Huang F, Zhang Q, Ma H, Lv Q, Zhang T. Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol 2014;7:1093-100.
26. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010;107:8788-93.
27. Wang J, Kuropatwinski K, Hauser J, Ross MR, Zhou Y, Conway A, et al. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther 2007;6:1143-50.
28. Davidson D, Coulombe Y, Martinez-Marignac V, Amrein L, Grenier J, Hodkinson K, et al. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs 2012;30:1248-56.
29. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
30. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 2009;23:537-48.